SRI 31215 (TFA)
SRI 31215 (TFA) is a Matriptase/Hepsin/hepatocyte growth factor activator (HGFA) triplex inhibitor and mimics the activity of HAI-1/2 (endogenous inhibitors of HGF activation) . SRI 31215 has potent inhibitory activity against matriptase, hepsin and HGFA with IC50 values of 0.69 μM, 0.65 μM and 0.30 μM, respectively. SRI 31215 can be used for the research of cancer[1].
Product Specifications
CAS Number
1832686-44-8
UNSPSC
12352005
Target
C-Met/HGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Neuroscience-Neuromodulation
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sri-31215-tfa.html
Purity
98.53
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
N=C(C1=CC=CC(N2CC(C)CN(CC3CCN(CC4=CC=CC=C4)CC3)C2=O)=C1)N.OC(C(F)(F)F)=O
Molecular Formula
C27H34F3N5O3
Molecular Weight
533.59
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Biomedicines. 2025 Mar 28;13 (4) :811.|Int J Mol Sci. 2025 Mar 5;26 (5) :2308.|Mol Cancer Ther. 2023 Jun 1;22 (6) :765-777.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
